Muhammad usman Akbar

Mr. Muhammad usman Akbar

Gomal University, Dera Ismail Khan, Khyber Pakhtunkhwa, Pakistan
+1
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2022 in ACS Omega
Verified
Journal Article
Open access
MAMuhammad usman Akbar
Muhammad usman Akbar
MBMuhammad Badar
Muhammad Badar
MZMuhammad Zaheer
Muhammad Zaheer
Along with the increasing incidence of cancer and drawbacks of traditional drug delivery systems (DDSs), developing novel nanocarriers for sustained targeted-drug release has become urgent. In this regard, metal-organic frameworks (MOFs) have emerged as potential candidates due to their structural flexibility, defined porosity, lower toxicity, and biodegradability. Herein, a FeMn-based ferromagnetic MOF was synthesized from a preassembled Fe2Mn(μ3-O) cluster. The introduction of the Mn provided the ferromagnetic character to FeMn-MIL-88B. 5-Fluoruracil (5-FU) was encapsulated as a model drug in the MOFs, and its pH and H2S dual-stimuli responsive controlled release was realized. FeMn-MIL-88B presented a higher 5-FU loading capacity of 43.8 wt % and rapid drug release behavior in a tumor microenvironment (TME) simulated medium. The carriers can rapidly release loaded drug of 70% and 26% in PBS solution (pH = 5.4) and NaHS solution (500 μM) within 24 h. The application of mathematical release models indicated 5-FU release from carriers can be precisely fitted to the first-order, second-order, and Higuchi models of release. Moreover, the cytotoxicity profile of the carrier against human embryonic kidney cells (HEK293T) suggests no adverse effects up to 100 μg/mL. The lesser toxic effect on cell viability can be attributed to the low toxicity values [LD50 (Fe) = 30 g·kg-1, (Mn) = 1.5 g·kg-1, and (terephthalic acid) = 5 g·kg-1] of the MOFs structural components. Together with dual-stimuli responsiveness, ferromagnetic nature, and low toxicity, FeMn-MIL-88B MOFs can emerge as promising carriers for drug delivery applications.

12 October 2023 in Materials Advances
Verified
Journal Article
Open access
PDF file
MAMuhammad usman Akbar
Muhammad usman Akbar
AAArslan Akbar
Arslan Akbar
USUmair Ali Khan Saddozai
Umair Ali Khan Saddozai
MKMalik Ihsan Ullah Khan
Malik Ihsan Ullah Khan
MZMuhammad Zaheer
Muhammad Zaheer
MBMuhammad Badar
Muhammad Badar
By combining two different ligands and metals, MOFs can be fine-tuned for effective encapsulation and delivery of two anticancer drugs.

19 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
USUmair Ali Khan Saddozai
Umair Ali Khan Saddozai
FWFengling Wang
Fengling Wang
Saadullah KhattakSaadullah Khattak
Saadullah Khattak
MAMuhammad usman Akbar
Muhammad usman Akbar
MBMuhammad Badar
Muhammad Badar
XGXiangqian Guo
Xiangqian Guo
Malignant pleural mesothelioma (MPM) is a fatal disease of respiratory system. Despite the availability of invasive biomarkers with promising results, there are still significant diagnostic and therapeutic challenges in the treatment of MPM. One of three main mesothelioma cell types, epithelioid mesothelioma makes up approximately 70% of all mesothelioma cases. Different observational findings are under process, but the molecular heterogeneity and pathogenesis of epithelioid malignant pleural mesothelioma (eMPM) are still not well understood. Through molecular analysis, expression profiling data were used to determine the possibility and optimal number of eMPM molecular subtypes. Next, clinicopathological characteristics and different molecular pathways of each subtype were analyzed to prospect the clinical applications and advanced mechanisms of eMPM. In this study, we identified two distinct epithelioid malignant pleural mesothelioma subtypes with distinct gene expression patterns. Subtype I eMPMs were involved in steroid hormone biosynthesis, porphyrin and chlorophyll metabolism, and drug metabolism, while subtype II eMPMs were involved in rational metabolism, tyrosine metabolism, and chemical carcinogenesis pathways. Additionally, we identified potential subtype-specific therapeutic targets, including CCNE1, EPHA3, RNF43, ROS1, and RSPO2 for subtype I and CDKN2A and RET for subtype II. Considering the need for potent diagnostic and therapeutic biomarkers for eMPM, we are anticipating that our findings will help both in exploring underlying mechanisms in the development of eMPM and in designing targeted therapy for eMPM.

21 June 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
USUmair Ali Khan Saddozai
Umair Ali Khan Saddozai
FWFengling Wang
Fengling Wang
MAMuhammad usman Akbar
Muhammad usman Akbar
LZLu Zhang
Lu Zhang
YAYang An
Yang An
XGXiangqian Guo
Xiangqian Guo
Pheochromocytoma (PCC) is a rare neuroendocrine tumor of the adrenal gland with a high rate of mortality if diagnosed at a late stage. Common symptoms of pheochromocytoma include headache, anxiety, palpitation, and diaphoresis. Different treatments are under observation for PCC but there is still no effective treatment option. Recently, the gene expression profiling of various tumors has provided new subtype-specific options for targeted therapies. In this study, using data sets from TCGA and the GSE19422 cohorts, we identified two distinct PCC subtypes with distinct gene expression patterns. Genes enriched in Subtype I PCCs were involved in the dopaminergic synapse, nicotine addiction, and long-term depression pathways, while genes enriched in subtype II PCCs were involved in protein digestion and absorption, vascular smooth muscle contraction, and ECM receptor interaction pathways. We further identified subtype specific genes such as ALK, IGF1R, RET, and RSPO2 for subtype I and EGFR, ESR1, and SMO for subtype II, the overexpression of which led to cell invasion and tumorigenesis. These genes identified in the present research may serve as potential subtype-specific therapeutic targets to understand the underlying mechanisms of tumorigenesis. Our findings may further guide towards the development of targeted therapies and potential molecular biomarkers against PCC.

25 June 2025 in Advanced Therapeutics
Verified
Journal Article
Open access
MAMuhammad usman Akbar
Muhammad usman Akbar
WGWeiwei Guo
Weiwei Guo
XSXin Shen
Xin Shen
YFYimeng Fang
Yimeng Fang
YLYilin Liu
Yilin Liu
YCYaping Chen
Yaping Chen
Central nervous system (CNS) diseases pose a significant global health challenge, currently affecting one in six individuals worldwide. Despite extensive research into their molecular and cellular mechanisms, effective treatment remains elusive due to the inherent complexity of CNS disorders and the protective constraints of the blood‐brain barrier (BBB).Conventional monotherapies often fail to produce satisfactory outcomes. In recent years, nanomaterials have emerged as promising therapeutic platforms—offering enhanced pharmacokinetics, improved biodistribution, and reduced systemic toxicity. More importantly, multifunctional nanomaterials can be engineered to actively target the brain parenchyma and lesion sites, co‐deliver multiple therapeutics, and modulate neuroimmune responses synergistically. Their tunability and adaptability to diverse pathological contexts make them well‐suited to address the multifactorial nature of CNS diseases. This review discusses the mechanisms contributing to therapeutic resistance in common brain disorders and highlights the potential of engineered nanomaterials that can address the multifaceted disease microenvironment. We also identify current challenges and prospects for the rational design of multifunctional nanoplatforms tailored to CNS disease treatment.

11 July 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
MAMuhammad usman Akbar
Muhammad usman Akbar
AAArslan Akbar
Arslan Akbar
USUmair Ali Khan Saddozai
Umair Ali Khan Saddozai
MKMalik Ihsan Ullah Khan
Malik Ihsan Ullah Khan
MZMuhammad Zaheer
Muhammad Zaheer
MBMuhammad Badar
Muhammad Badar
Combination therapy has emerged as a promising strategy due to its synergistic therapeutic pathways that enhance anticancer efficacy and limits the emergence of drug resistance. In this work, MIL-88B type multivariate (MTV-1) nanocarriers based on mixed linker (1, 4-benzenedicarboxylic acid and biphenyl-4,4'-dicarboxylic acid ) and metals (iron and cobalt) were synthesized. Presence of the distinct linkers modified the pore makeup of MTV-1 and facilitated the co-encapsulation of two anticancer drugs of varying molecular sizes; 5-Fluorouracil (5-FU) and Curcumin (CUR). The drug loading measurements on MTV-1@5-FU+CUR represented a loading capacity of 15.9wt% for 5-FU and 9.3wt% for CUR, respectively. They further exhibited a pH-responsive drug release pattern with higher concentrations of 5-FU and CUR released at pH 5.5 (simulating cancer microenvironment) compared to pH 7.4 (physiological environment). Moreover, we also demonstrated that MTV-1 MOFs, due to the presence of mixed valence metal ions, could perform peroxidase-like activity and catalyzes H2O2 decomposition to produce •OH radicals for chemodynamic therapy. Cell cytotoxicity assays exhibited significant inhibitory effects of MTV-1@5-Fu+CUR against HepG2 cells with an IC50 of 78.7 g/mL. Together with dual-drug loading, pH-responsive release, and chemodynamic therapy, MTV-1 show excellent potential for multifunctional anticancer treatment.